Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 500
- Registration Number
- NCT02559778
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸St. Lukes, Boise, Idaho, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
- Conditions
- Head and Neck Squamous Cell CarcinomaRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Salivary Gland CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage III Major Salivary Gland CarcinomaStage III Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage III Nasopharyngeal CarcinomaStage IV Nasopharyngeal CarcinomaStage IVA Major Salivary Gland Carcinoma
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT02538510
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- SEARCH Research Foundation
- Target Recruit Count
- 15
- Registration Number
- NCT02475915
- Locations
- 🇹🇭
SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
- Conditions
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02420613
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Epigenetic Reprogramming in Relapse AML
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Michael Burke
- Target Recruit Count
- 3
- Registration Number
- NCT02412475
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
Reversing Therapy Resistance With Epigenetic-Immune Modification
- Conditions
- Interventions
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 38
- Registration Number
- NCT02395627
- Locations
- 🇺🇸
University of California, San Francisco Medical Center, San Francisco, California, United States
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 23
- Registration Number
- NCT02349867
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Research In Viral Eradication of HIV Reservoirs
- Conditions
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 60
- Registration Number
- NCT02336074
- Locations
- 🇬🇧
Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom
🇬🇧Central and North West London NHS Foundation Trust, London, United Kingdom
🇬🇧Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.